What are the Steps to Ensure an Unbiased Comparator Arm?

The desire to lower the #DrugDevelopment costs and speed up trials, together with higher availability of real-world data, has forced the regulators to embrace the use of SCAs in #ClinicalDevelopment.

In oncological studies, the use of SCA (synthetic control arms) has successfully lead to the expedited approval of multiple innovative therapies.

For example, the EFGR modulator Tagrisso by AstraZeneca received approval from the FDA in only three years from the first patient receiving the dose due to the use of SCAs.

In non-oncological fields, SCA trials are commonly used in combination with natural history studies, for example, the trial performed for approval for Zolgensma, a gene therapy indicated for spinal muscular atrophy.

In order to choose the right approach for designing SCAs, different factors come into play such as the types of data available, the anticipated length of a trial, the desired sample size, and the potential biases.

The possibility of sampling bias while using real-world data is higher but can be quantified and minimized by adjusting the use of propensity scores.

Deciding the best SCA approach is important to make sure that the findings are robust and necessary transparency is maintained.

 

3 Key Points

  1. The use of SCAs in clinical trials has been positively embraced by most regulators due to its ability to reduce the total costs and increase the speed of drug development.
  2. In order to choose an appropriate approach to designing SCAs, it is important to take into account factors like the different types of data available, the desired sample size, and the anticipated duration of the trial.
  3. In order to eliminate biases, propensity score (the probability of enrollment into a given arm of a trial) must be used.

Source: http://bit.ly/2Q1t7Uz

#ClinicalData, #DataManagement, #ClinicalDataManagement, #MedidataSolutions, #ClinicalTrials, #SCA, #SyntheticControlArms, #Comparator

P.S. Stay up-to-date with what’s new in clinical trials! Get the latest articles summarized and delivered free to your e-mail inbox. Click here to learn more.

Latest news

ACTide by Nubilaria against COVID-19

DECEIVER trial for COVID-19 related ARDS intensive care

Read more
Nubilaria ACTide @ Medical device trials

Medical Device Trials – Virtual Experience

Read more
Nubilaria ACTide @ Direct to Patient digital experience

Direct-to-Patient and Virtual Clinical Trials – Digital Experience

Read more

Want more information about our solutions?
Contact us today.

I've read and accept theTerms and Conditions and the Privacy Policy
   I would like to receive information about products and services via traditional mail, telephone, email and automated communication systems